The most recently added clinical trials across every neurology subspecialty — one feed, updated continuously. Get them weekly by email or via RSS.
Among 1,043 patients with ICH, 78 (7.5%) had a macrovascular cause; the MACRO score (age, ICH location, and 4 MRI small-vessel-disease markers) achieved an optimism-adjusted c-statistic of 0.90 (95% CI 0.88–0.93) MACRO w…
View trial →Mean annualized relapse rate (ARR) fell sharply over 15 years: AQP4+NMOSD 0.45 (0.41–0.48) → 0.04 (0.03–0.05); MOGAD 0.35 (0.31–0.39) → 0.10 (0.08–0.12), both p
View trial →THC + CBD (6% THC + 11% CBD) was superior to placebo for 2-h pain relief (67.2% vs 46.6%; OR 2.85 [1.22–6.65], p=0.016), 2-h pain freedom (34.5% vs 15.5%; OR 3.30 [1.24–8.80], p=0.017), and 2-h most-bothersome-symptom fr…
View trial →In adults with chronic migraine (baseline 22.0 headache days/month), onabotulinumtoxinA reduced headache days by −9.2 at 60 weeks and −10.7 at 108 weeks (both P
View trial →Meta-analysis pooling RCTs of complement inhibitors and FcRn blockers in generalized AChR antibody-positive myasthenia gravis Both targeted biologic classes were evaluated for MG-ADL/QMG response and adverse-event profil…
View trial →Systematic review and meta-analysis pooling the diagnostic accuracy (sensitivity and specificity) of muscle ultrasound for fasciculation detection in ALS Compared ultrasound against electromyography or clinical diagnosti…
View trial →Efficacy and safety results were not reported in the available source abstract. The primary endpoint was change from baseline in MG-ADL at week 24 (mITT population); no values, effect sizes, or p-values were provided. Re…
View trial →All 34 participants (12 CS-untreated, 22 CS-treated) completed the 12-week study and continued into EAP Canada; most treatment-emergent adverse events were mild No negative effect on growth: CS-untreated boys maintained…
View trial →Phase 3 randomized placebo-controlled trial of once-monthly intramuscular GA Depot in relapsing MS. The trial assessed efficacy on relapse rate and MRI activity, along with safety, relative to placebo. Quantitative effic…
View trial →Meta-regression across MS randomized controlled trials assessed whether treatment effects on NfL track with treatment effects on clinical and MRI disease-activity endpoints. The analysis quantified the strength of the tr…
View trial →Over the 240-week (5-year) extension, mean annualized relapse rate (ARR) was 0.143 (95% CL 0.123–0.167) in continuous ponesimod (P20/P20) vs 0.184 (95% CL 0.158–0.213) in the teriflunomide-to-ponesimod switch group (T14/…
View trial →IHS accounted for 3.8% of ischemic stroke admissions and remained associated with greater severity and worse outcomes than COS despite MT-era advances Adjusted in-hospital mortality was more than double (aOR 2.27, 95% CI…
View trial →Primary major ischemic events at 90 days (ischemic stroke, MI, or ischemic vascular death): 5.0% DAPT vs 6.5% aspirin (HR 0.75, 95% CI 0.59–0.95, P=0.02; NNT≈65). Ischemic stroke alone: 4.6% vs 6.3% (HR 0.72, 0.56–0.92,…
View trial →Seropositive patients had 34% lower relapse risk vs seronegative (RR 0.66; 95% CI 0.49-0.89; p=0.007; I²=0%) RCT-only subgroup showed 59% relative risk reduction favoring seropositive (RR 0.41; 95% CI 0.25-0.69; p=0.0008…
View trial →TER-UBL switchers had a 58.4% ARR reduction at 1 year after switching (0.182 vs 0.076; RR 0.42; 95% CI 0.29-0.60; P
View trial →Primary (90-day mRS shift): acOR 1.13 (95% CI 0.77–1.65); trial stopped early for futility at 2nd interim (posterior probability of superiority 46%). mRS 0–2 at 90 days: 19.3% vs 15.6% (acOR 1.34, 0.81–2.22). 90-day mort…
View trial →Functional independence (mRS 0-2) at 90 days: 58.6% thrombectomy vs 46.6% control (adjusted rate ratio 1.24, 95% CI 1.07-1.44, P=0.004) Symptomatic intracranial hemorrhage: 4.7% thrombectomy vs 2.2% control 90-day mortal…
View trial →Functional independence (mRS 0-1) at 90 days: 40% (alteplase) vs 26% (control), adjusted RR 1.52 (95% CI 1.14-2.02), P=.004 Unadjusted absolute risk difference: 13.98% (95% CI 4.50%-23.45%) Symptomatic intracranial hemor…
View trial →Median reduction in countable motor seizure frequency: -59.8% with bexicaserin vs -17.4% with placebo Reductions observed across DEE subtypes: Dravet syndrome -74.6%, Lennox-Gastaut syndrome -50.8%, DEE Other -65.5% 60.0…
View trial →Amifampridine add-on did NOT improve MGII scores vs placebo (30mg: mean diff −1.0, 95% CI −4.1 to 2.0, p=0.681; 60mg: mean diff −1.7, 95% CI −4.7 to 1.4, p=0.379) No significant association between pharmacokinetic parame…
View trial →Primary carotid reocclusion at 24h: 7.2% vs 16.8% (P=0.036), NNT=10.4. Intra-stent aggregation: 8.6% vs 16.8% (significant). sICH 7.9% vs 3.6% (NS). 90-day mRS 0-2: 59.6% vs 70.8% (NS).
View trial →Primary 90-day mRS 0-2: 49.3% vs 43.3%, aRR 1.15 (1.03-1.27). 90d mRS shift: cOR 1.22 (1.01-1.48). sICH 11.9% vs 19.4% (NS); mortality 18.3% vs 19.0% (NS). Tirofiban increased functional independence without increasing s…
View trial →Primary 90-day mRS 0-2: no significant difference between session-intensity arms in either NIHSS stratum. Mild stroke (NIHSS
View trial →Primary 90-day mRS 0-2: 41.6% vs 40.7% (superiority failed; Pnoninf = 0.001). Final mTICI 2b-3: 49.7% vs 48.3% (NS). sICH 1.2% vs 1.2% (NS); 90-day mortality 37.1% vs 35.9% (NS). EVT alone was non-inferior to IV tPA + EV…
View trial →Primary 90-day mRS full analysis: 1.06 (0.79-1.43); per-protocol 1.10 (0.81-1.50) — non-inferiority not claimed. 90d mRS 0-2: 53% vs 48% (NS). Final mTICI >=2b: 87% vs 83% (PP sig). Carotid reocclusion 24h: 19% vs 45% (s…
View trial →Primary 90-day mRS 0-2: 54.7% vs 39.8% (P=0.018), NNT=7. 90d mRS shift aOR 1.72 (1.12-2.05). sICH 7.0% vs 9.0% (NS); any ICH 21.7% vs 29.3% (NS). Sham control had lower-than-expected good-outcome rate (room-temp vs body-…
View trial →Primary PHQ-9 at 3 months: 4 (1-8) vs 4 (1-8) vs 5 (2-9). MI vs UC: P=0.025. AC vs UC: P=0.058. ~25% attended no session at all.
View trial →Achieved group difference in SBP: 8 mmHg. Primary hierarchical composite (CV death, stroke, MI, HF hospitalization) win ratio: unmatched 1.02 (0.90-1.15); matched 1.02 (0.90-1.15). No reduction in major CV events vs stan…
View trial →24h reperfusion without sICH: 86.3% vs 27.7% (P
View trial →Primary symptomatic and confirmed fatal/nonfatal VTE: 4.4% vs 7.7%, HR 0.58 (0.20-1.70). Bleeding: 4% vs 5% (NS); mortality 2.6% vs 0.0% (NS). Composite recurrent VTE + major bleeding: 6.2% vs 9.1% (NS). Cluster RCT term…
View trial →Primary eTICI 2b-3 on initial angiogram without sICH: 15% vs 18% vs 19% vs 21% (NS across doses). Versus historical 20% (TNK) or 10% (tPA). sICH 1.3% (overall); mortality 13.3% (overall). Did not meet pre-specified promi…
View trial →Primary 90-day mRS shift: NS. 90d mRS 0-2: 50.8% vs 46.9% (NS); sICH 3.1% vs 6.2% (NS). Any ICH: 26.9% vs 45.3% (P=0.002). Ipsi-tympanic temp drop ~1.05 degC documented.
View trial →Primary 90-day mRS shift: cOR 1.46 (1.03-2.09). sICH 10.9% vs 5.7% (NS). SAE 17.6% vs 10.3% (NS); malignant edema 14.5% vs 10.3% (NS). ICAD 64%; eTICI 2c-3 84%.
View trial →Primary 90-day mRS cOR: 0.58 (0.28-1.19), P=0.14. 90d mRS 0-2: 39% vs 55% (NS); mTICI 2b-3: 96% vs 98% (NS). 90d mortality 17% vs 8%; any ICH 28% vs 17%; sICH 2% vs 4%. Trial stopped for futility; unexpected trend toward…
View trial →Primary 90-day mRS 0-2: 60.0% vs 46.7% (P=0.005). Ordinal mRS: OR 1.43 (1.02-2.00). HT 22.3% vs 31.6% (P=0.03); sICH 3.5% vs 3.9% (NS). Trial terminated early due to funding restraints.
View trial →In anterior LVO stroke 24–72 hours from last known well with perfusion mismatch, EVT improved the 90-day mRS distribution versus best medical management (cOR 0.57, 95% CI 0.39–0.84, P=0.005; adjusted OR 0.47, 95% CI 0.32…
View trial →Median achieved SBP: 170 vs 141 mmHg. Primary 90-day mRS: 2 (1-4) vs 2 (1-4), P=0.49. sICH 2.1% vs 2.1%. 90-day mortality 15.2% vs 12.1% (NS). No benefit from restrictive SBP target 130-180 mmHg; supports current guideli…
View trial →Primary 90-day mRS 0-1: 69.4% vs 50.0%, RR 1.39 (1.14-1.70). 90d mRS 0-2: 82.6% vs 66.9% (sig). sICH at 48h 2.1% vs 1.9% (NS); 90d mortality 0.7% vs 0.0% (NA). END within 7d: 13.9% vs 31.4% (sig).
View trial →Incident ischemic stroke: 6.6% (asundexian) vs 8.8% (placebo), NNT=46. Asundexian arm: less disabling/fatal stroke, lower NIHSS at event. Lower need for EVT among incident strokes on asundexian. Similar rates of hemorrha…
View trial →Sensitivity: 0.926 (0.889-0.957). Specificity: 0.908 (0.908-0.961). Non-inferiority overall not met (95% margin). Performance improved in NIHSS >=10 and at experienced centers.
View trial →Early reperfusion (post-rand angio): 39% vs 36% (NS). Late reperfusion (24h perfusion): 51% vs 40% (NS). 90-day mRS 0-2: 28% vs 38% (NS) - numeric trend toward harm. sICH 5.2% vs 8.6% (NS); mortality 25% vs 17% (NS). >50…
View trial →Alive without dementia: 56.3% vs 55.0% (NS). MOCA (ordinal): OR 1.41 (0.98-1.96). WMH number: 49 vs 48 (NS); recent subcortical infarct 1.5% vs 1.2%. CMB number 1 (0-3) vs 1 (0-3); CSS 1 (1-1) vs 1.5 (1-2). No difference…
View trial →NXY-059 significantly improved the distribution of modified Rankin scale scores at 90 days vs placebo (P=0.038; common OR 1.20, 95% CI 1.01-1.42) No improvement in neurologic functioning by NIHSS (between-group differenc…
View trial →EVT improved 90-day mRS distribution vs medical management (median 4 [IQR 3-6] vs 5 [4-6]; aGenOR 1.63, 95% CI 1.42-1.88, p
View trial →No difference in 12-month mRS distribution between EVT + BMT and BMT alone (adjusted common OR 0.81, 95% CI 0.59–1.12; p=0.20) Median mRS score was 2 (IQR 1–4) in both groups Overall survival was similar between groups (…
View trial →Excellent outcome (mRS 0-1) at 90 days: 63.8% tirofiban vs 52.2% placebo (RR 1.22; 95% CI 1.02-1.46; P=.03) Symptomatic intracranial hemorrhage within 48h: 0.9% tirofiban vs 0% placebo 90-day mortality: 0.6% tirofiban vs…
View trial →Early DAPT achieved excellent functional outcome (mRS 0–1) at 90 days in 68.7% vs 62.0% with placebo (RR 1.11, 95% CI 1.03–1.20; p=0.0089) Symptomatic intracranial haemorrhage within 36 h occurred in 0.9% (DAPT) vs 0.7%…
View trial →Recurrent stroke occurred in 4.6% (triple pill) vs 7.4% (placebo); HR 0.61 (95% CI 0.41–0.92), P=0.02 Mean systolic BP during follow-up: 127 vs 138 mm Hg (between-group difference 9 mm Hg) Major cardiovascular events: 6.…
View trial →Absolute bioavailability of subcutaneous (vial) lecanemab was 49.7% (90% CI: 43.5-56.8) relative to IV Autoinjector produced ~25% higher Cmax and ~20% higher AUC than vial/syringe; formal bioequivalence NOT demonstrated…
View trial →Modified titration reduced ARIA-E frequency to 13.7% vs 23.7% with standard dosing at 24 weeks (94.1% probability of ≥20% RRR, posterior RRR 0.405 ± 0.123) Dose skipping (18.6%) and Cmax (18.3%) arms did not meet the pre…
View trial →Brexpiprazole 2 or 3 mg/d reduced CMAI total score significantly more than placebo at week 12 (mean change −22.6 vs −17.3; LSM difference −5.32; 95% CI −8.77 to −1.87; P=.003) Cohen d effect size 0.35 No TEAE had ≥5% inc…
View trial →Stereotactic radiation reduced composite MD Anderson Symptom Inventory–Brain Tumor score (change −0.32) vs hippocampal-avoidance whole brain radiation (change +0.74); mean difference −1.06 (95% CI, −1.54 to −0.…
View trial →Over 5 years, mean annualized relapse rate was 0.143 (95% CL: 0.123-0.167) for P20mg/P20mg and 0.184 (95% CL: 0.158-0.213) for T14mg/P20mg 44.3% of P20mg/P20mg and 49.5% of T14mg/P20mg participants experienced relapse NE…
View trial →No significant between-group difference for the primary end point of change in combined evoked potential latency at 6 months (β = −0.31, 95% CI −1.84 to 1.22, p = 0.668) MSC group showed reduced cerebral atrophy on MRI a…
View trial →Primary outcome (mRS 4-6 at day 90): 21.6% glenzocimab vs 15.3% placebo (OR 1.51 [95% CI, 0.90-2.54]; P=0.120) — no significant difference No statistically significant difference in any secondary outcomes No major safety…
View trial →Combination therapy of abrupt withdrawal + oral prevention + greater occipital nerve block (W+P+Nb) was the most effective, reducing monthly headache days by -10.6 (95% CI: -15.03 to -6.16) vs control Restriction of over…
View trial →All three treatments significantly reduced monthly headache days at 3 months (P < 0.001) Galcanezumab + prednisone achieved the greatest reduction: 25 → 7 days (IQR 5–10), vs galcanezumab alone 25 → 10 days (IQR 5–14), v…
View trial →Single 750-mg infusion of Lu AG09222 reduced migraine days by −6.2/month vs −4.2 with placebo (difference −2.0 days; 95% CI −3.8 to −0.3; P=0.02) over weeks 1–4 ≥50% reduction in migraine days achieved in 32% (Lu AG09222…
View trial →Atogepant 30mg BID reduced MMDs vs placebo by -2.7 days (95% CI -4.0 to -1.4) in patients with acute medication overuse Atogepant 60mg QD reduced MMDs vs placebo by -1.9 days (95% CI -3.2 to -0.6) in patients with acute…
View trial →Primary endpoint (≥50% headache frequency reduction at 12 months) achieved by 78.4% in TaU+MIND vs 48.3% in TaU alone (p
View trial →Both galcanezumab doses (120 mg and 240 mg) significantly reduced monthly migraine headache days vs placebo in patients with baseline medication overuse (p ≤ 0.001) EVOLVE-1/-2 (episodic migraine) overall LS mean change…
View trial →In the medication overuse subgroup (n=274), erenumab 70 mg and 140 mg reduced monthly migraine days by −6.6 days each vs −3.5 days with placebo at month 3 ≥50% MMD reduction achieved by 36% (70 mg, OR 2.67 [1.36–5.22]) a…
View trial →At 12 months, EVT + BMT did not reduce disability compared to BMT alone (adjusted common OR 0.81, 95% CI 0.59–1.12; p=0.20); median mRS was 2 in both groups. Overall survival was similar between groups (HR 1.46, 95% CI 0…
View trial →Amantadine-IR halved dyskinesia incidence at 18 months vs placebo: 11% vs 22% (P=0.025); adjusted OR 0.43 (95% CI 0.19–0.98, P=0.045) Amantadine-IR group required 70 mg/day less levodopa dose increase over 18 months (95%…
View trial →Functional independence (mRS 0–2) at 90 days: 44.2% (tenecteplase+EVT) vs 43.2% (EVT alone); adjusted RR 1.01 (95% CI, 0.83–1.24); P = 0.89 Risk difference: 0.99% (95% CI, −8.84% to 10.83%) — no clinically meaningful ben…
View trial →Subcutaneous infusion reduced daily OFF-time by a mean of 1.98 hours vs. oral levodopa (p = 0.0004; moderate-quality evidence across 7 studies, 725 patients) ND0612 reduced OFF-time by 1.42 h/day; foslevodopa/foscarbidop…
View trial →Intensive BP control (targeting SBP
View trial →CRST A+B for the treated hand decreased from 21.0 to 8.8 at 12 months (−58%; p
View trial →Nerinetide did not improve functional independence at 90 days: mRS 0–2 achieved in 45% (nerinetide) vs 46% (placebo); OR 0.97 (95% CI 0.72–1.30); p=0.82 No excess serious adverse events with nerinetide — drug was safe bu…
View trial →No improvement in favorable outcomes at 3 months: 32% abciximab (71/221) vs 33% placebo (72/218) in the primary cohort (P=0.944) Abciximab significantly increased symptomatic or fatal intracranial hemorrhage within 5 day…
View trial →NXY-059 did not reduce disability: mRS distribution at 90 days showed no significant difference vs placebo (P = 0.33; OR 0.94, 95% CI 0.83–1.06) Trichotomized mRS analysis confirmed no benefit (OR 0.92, 95% CI 0.80–1.06)…
View trial →Anti-CGRP mAbs significantly increased the ≥50% responder rate vs placebo in episodic cluster headache (eCH) (OR=1.65, 95% CI 1.07–2.55, p=0.02) Galcanezumab 300 mg and eptinezumab 400 mg were each individually superior…
View trial →Vaporized 6% THC+11% CBD was superior to placebo for 2-hour pain relief (67.2% vs 46.6%, OR 2.85 [1.22–6.65], p=0.016), 2-hour pain freedom (34.5% vs 15.5%, OR 3.30 [1.24–8.80], p=0.017), and 2-hour MBS freedom (60.3% vs…
View trial →Soticlestat failed to reduce major motor drop (MMD) seizure frequency versus placebo: placebo-adjusted median difference −1.17% (95% CI −13.02 to 9.99, p = .785) over the full 16-week treatment period and 2.43% (95% CI −…
View trial →Adjunctive amantadine-IR halved 18-month dyskinesia incidence versus placebo (11% vs 22%, P=0.025; OR 0.43, 95% CI 0.19–0.98) Amantadine-IR group required significantly smaller levodopa dose increases over 18 months (70…
View trial →Both levetiracetam (OR 1.80) and brivaracetam (OR 1.86) significantly increased somnolence risk vs. placebo Levetiracetam was additionally associated with irritability (OR 2.55) and asthenia (OR 1.71) Brivaracetam carrie…
View trial →Left-sided naming decline was significantly lower with MRgLITT (9%, 95% CI 3%–22%) than open resection (43%, 95% CI 27%–61%; p < .0001), with MRgLITT retaining a protective effect after adjusting for seizure outcomes (β…
View trial →Neither co-primary outcome reached significance after 5–8 years of treatment: API ADAD composite (p=0.43) and FCSRT-CI (p=0.16) showed no significant benefit with crenezumab vs placebo Secondary and exploratory outcomes…
View trial →Valacyclovir 4 g/d was associated with significantly greater cognitive worsening than placebo: ADAS-Cog change 10.86 vs 6.92 at 78 weeks (difference 3.93, 95% CI 1.03–6.83; P = .01) No significant between-group differenc…
View trial →No significant improvement in functional outcome: mRS 0-2 at 180 days occurred in 46% (rFVIIa) vs 45% (placebo); adjusted common OR 1.09 (95% CI 0.79-1.51, p=0.61) -- trial stopped for futility. rFVIIa significantly slow…
View trial →IV alteplase at 4.5–24 hours improved 90-day functional independence in posterior circulation stroke not eligible for thrombectomy (mRS 0–2: 89.6% vs 72.6%, aRR 1.16 [1.03–1.30], P=0.01). sICH within 36 hours was rare an…
View trial →Low-intensity monitoring showed weak evidence of non-inferiority to standard monitoring (RR 1.03, 95% CI 0.92-1.15, p=0.057) No increase in symptomatic ICH (0.2% vs 0.4%) or serious adverse events (11.1% vs 11.3%) Interv…
View trial →Active BP lowering did not significantly improve 90-day functional outcomes vs no lowering (aOR 1.27, 95% CI 0.96–1.68 for worse outcome with active strategy) Despite higher IVT rates (94% vs 52%, p
View trial →GTN did not improve functional outcome: mRS at 90 days was identical in both groups (median 2, aOR 0.97, 95% CI 0.65–1.47) No blood pressure-lowering effect was detected at hospital admission despite median prehospital S…
View trial →Low-intensity post-IVT monitoring was feasible and safe in selected low-risk patients (NIHSS
View trial →Primary outcome (mRS at 90 days) was nonsignificantly worse with GTN: median 5 in both groups, aOR 1.87 (95% CI 0.98–3.57, p=0.058); all 4 sensitivity analyses were statistically significant and favored sham GTN was asso…
View trial →Semaglutide reduced MACE (CV death, nonfatal MI, nonfatal stroke): 6.6% vs 8.9%, HR 0.74 (95% CI 0.58–0.95), p
View trial →Eptinezumab was well tolerated: 81% had at least one TEAE (mostly mild/moderate), only 3% withdrew due to TEAEs, and there were no treatment-related serious adverse events and no deaths. Monthly cluster headache attacks…
View trial →None of the 6 coprimary endpoints (verbal memory, visual memory, global cognitive composite, hippocampal volume, cortical gray matter, BDNF) met the prespecified significance threshold of P
View trial →DMF reduced sGFAP by ~18% over 2 years (p
View trial →